Acellular vs whole cell whooping cough vaccines

Evidence Summaries

Level of Evidence = B

Multi-component acellular pertussis vaccines appear to be effective, and show less adverse effects than whole-cell pertussis vaccines for the primary series as well as for booster doses.

A Cochrane review ¹ included 6 efficacy trials with a total of 46,283 participants and 52 safety trials with a total of 136,541 participants. Meta-analysis was not possible. The efficacy of multi-component (≥ 3) vaccines varied from 84% to 85% in preventing typical whooping cough, and from 71% to 78% in preventing mild pertussis disease. In contrast, the efficacy of one- and two-component vaccines varied from 59% to 75% against typical whooping cough, and from 13% to 54% against mild pertussis disease.

Multi-component acellular vaccines are more effective than low-efficacy whole-cell vaccines, but may be less effective than the highest-efficacy whole-cell vaccines. Most systemic and local adverse events were significantly less common with acellular than with whole-cell pertussis vaccines for the primary series as well as for the booster dose.

Comment: The quality of evidence is downgraded by inconsistency (heterogeneity in interventions and variability in results across studies).

References

1. Zhang L, Prietsch SO, Axelsson I et al. Acellular vaccines for preventing whooping cough in children. Cochrane Database Syst Rev 2014;(9):CD001478. [PMID:25228233]

Acellular vs whole cell whooping cough vaccines is a sample topic from the Evidence-Based Medicine Guidelines.

To view other topics, please sign in or purchase a subscription.

Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Learn more.

Citation

"Acellular Vs Whole Cell Whooping Cough Vaccines." Evidence-Based Medicine Guidelines, Duodecim Medical Publications Limited, 2019. Evidence Central, evidence.unboundmedicine.com/evidence/view/EBMG/455928/all/Acellular_vs_whole_cell_whooping_cough_vaccines.

Acellular vs whole cell whooping cough vaccines. Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. https://evidence.unboundmedicine.com/evidence/view/EBMG/455928/all/Acellular_vs_whole_cell_whooping_cough_vaccines. Accessed January 19, 2019.

Acellular vs whole cell whooping cough vaccines. (2019). In Evidence-Based Medicine Guidelines. Available from https://evidence.unboundmedicine.com/evidence/view/EBMG/455928/all/Acellular_vs_whole_cell_whooping_cough_vaccines

Acellular Vs Whole Cell Whooping Cough Vaccines [Internet]. In: Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. [cited 2019 January 19]. Available from: https://evidence.unboundmedicine.com/evidence/view/EBMG/455928/all/Acellular_vs_whole_cell_whooping_cough_vaccines

* When formatting your citation, note that all book, journal, and database titles should be italicized* Article titles in AMA citation format should be in sentence-case

TY - ELEC T1 - Acellular vs whole cell whooping cough vaccines ID - 455928 BT - Evidence-Based Medicine Guidelines UR - https://evidence.unboundmedicine.com/evidence/view/EBMG/455928/all/Acellular_vs_whole_cell_whooping_cough_vaccines PB - Duodecim Medical Publications Limited DB - Evidence Central DP - Unbound Medicine ER -